Primary Objectives:~To evaluate the number of ALPP-positive participants with treatment-related adverse events as assessed by CTCAE v4.0 after infusion with anti-ALPP CAR-T cells.~Secondary Objectives:~The number of patients experience objective response from anti-ALPP CAR-T cells treatment~To evaluate the progression-free survival (PFS) of anti-ALPP CAR-T cells in patients with ALPP-positive patients.~The number and percent of ALPP-CART cells in peripheral blood from ALPP-positive patients at 6 months after infusion
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive metastatic ovarian and endometrial cancer.